.png){kind=icon}
Return
Febuxostat
.png){kind=icon}
PRE
AI
DOI：10.2165/00003495-200868130-00006.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Febuxostat is an orally administered, non-purine, selective inhibitor of xanthine oxidase approved for the management of chronic hyperuricaemia in patients with gout. In a randomized, double-blind, dose-ranging study in patients with I-out and hyperuricaemia, significantly more recipients of febuxostat 40-120 mg/day than placebo had serum urate levels of <6.0 mg/dL after 4 weeks of treatment. Serum urate levels were reduced below 6.0 mg/dL at the last three monthly observations in a significantly greater proportion of patients with gout and hyperuricaemia receiving febuxostat 80 or 120 mg once daily than in those receiving allopurinol 300 mg once daily in a 52-week, randomized, double-blind trial (FACT). Similarly, febuxostat 80, 120 or 240 mg once daily showed significantly greater urate-lowering efficacy than allopurinol 100 or 300 mg once daily in a 28-week, randomized, double-blind, placebo-controlled trial (APEX) in patients with gout and hyperuricaemia. Long-term treatment with febuxostat for up to 4 years or more reduced the incidence of gout flares to (or close to) zero. Febuxostat was generally well tolerated in clinical trials, including extension studies lasting >= 4 years, with most treatment-related adverse events being mild to moderate in severity.
Keywords:
XANTHINE-OXIDASE INHIBITOR
NONPURINE SELECTIVE INHIBITOR
NON-PURINE
INTERIM ANALYSIS
OLDER-ADULTS
GOUT
HYPERURICEMIA
ALLOPURINOL
PHARMACOKINETICS
MANAGEMENT
Journal
IF:
14.4
Papers:
8.4K
Citations:
2.3W
Organization
Cited Papers
ShareSaveShareSaveShareSaveEffect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects.
PREAI
ShareSaveSelectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.png)
LIFE SCIENCES
LIFE SCIENCESIF5.1
PREAI
ShareSave
View more